Clinical-stage immuno-oncology company Imugene secured a patent for its oncolytic virotherapy CF33, including variants VAXINIA and CHECKvacc, from the Chinese Patent Office.

This follows previous grants in Japan and South Korea, ensuring composition and use rights until 2037 in China.

CF33 selectively targets and destroys tumour cells while activating the immune system against cancer.